Palvella Therapeutics, Inc. (PVLA)Healthcare | Biotechnology | Wayne, United States | NasdaqGM
146.03 USD
+1.27
(0.877%)
⇧
(July 13, 2026, 4 p.m.
EDT)
After hours: 143.11 -2.92 (-2.920%) ⇩ (July 13, 2026, 7:55 p.m. EDT) |
Hot Take ↕ | July 11, 2026, 6:52 a.m. EDT
Palvella is riding a powerful technical wave, trading significantly above its key moving averages after a sharp recovery in 2025. The short-term outlook is bullish because the stock is well above its 50-day and 200-day averages, supported by strong analyst consensus. However, the long-term view is cautious because the company's fundamentals remain precarious with negative earnings and cash flow, and the nine-year history shows a brutal overall decline. Investors should view the current rally as a momentum play fueled by capital raises and pipeline milestones, not a fundamental turnaround. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.131082 |
| AutoETS | 0.189046 |
| AutoARIMA | 0.189519 |
| MSTL | 0.196683 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 33% |
| H-stat | 2.68 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.358 |
| Excess Kurtosis | -0.96 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 8.774 |
| Market Cap | 2,094,485,504 |
| Forward P/E | -21.42 |
| Website | https://palvellatx.com |
As of July 11, 2026, 6:52 a.m. EDT: Implied volatility remains elevated across expirations, reflecting uncertainty. Call interest clusters at the $200 strike for August, hinting at upside hopes, while put volume concentrates at the $95 strike for July, indicating hedging against a potential pullback. The mix suggests a speculative stance rather than a directional bet.
| Attribute | Value |
|---|---|
| 52 Week Change | 4.2544465 |
| Address1 | 353 W. Lancaster Avenue |
| Address2 | Suite 200 |
| All Time High | 780.0 |
| All Time Low | 6.2 |
| Ask | 177.86 |
| Ask Size | 2 |
| Audit Risk | 7 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 371,320 |
| Average Daily Volume3 Month | 259,457 |
| Average Volume | 259,457 |
| Average Volume10Days | 371,320 |
| Bid | 105.3 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 16.23 |
| City | Wayne |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 146.03 |
| Current Ratio | 28.879 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 146.35 |
| Day Low | 137.53 |
| Debt To Equity | 8.774 |
| Display Name | Palvella Therapeutics |
| Earnings Call Timestamp End | 1,778,157,000 |
| Earnings Call Timestamp Start | 1,778,157,000 |
| Earnings Timestamp | 1,778,157,000 |
| Earnings Timestamp End | 1,778,157,000 |
| Earnings Timestamp Start | 1,778,157,000 |
| Ebitda Margins | 0.0 |
| Enterprise Value | 1,853,015,552 |
| Eps Current Year | -5.56538 |
| Eps Forward | -6.81818 |
| Eps Trailing Twelve Months | -4.17 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 122.7174 |
| Fifty Day Average Change | 23.3126 |
| Fifty Day Average Change Percent | 0.1899698 |
| Fifty Two Week Change Percent | 425.44464 |
| Fifty Two Week High | 161.38 |
| Fifty Two Week High Change | -15.350006 |
| Fifty Two Week High Change Percent | -0.09511715 |
| Fifty Two Week Low | 25.8 |
| Fifty Two Week Low Change | 120.229996 |
| Fifty Two Week Low Change Percent | 4.6600776 |
| Fifty Two Week Range | 25.8 - 161.38 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,420,209,000,000 |
| Float Shares | 9,577,434 |
| Forward Eps | -6.81818 |
| Forward P E | -21.417738 |
| Free Cashflow | -21,601,500 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 29 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.11648 |
| Held Percent Institutions | 0.96440005 |
| Implied Shares Outstanding | 14,342,844 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,713,830,400 |
| Last Split Factor | 1:80 |
| Long Business Summary | Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases. The company's lead product candidate is QTORIN rapamycin, a novel, 3.9% anhydrous topical gel that is in Phase 3 clinical trial for the treatment of microcystic lymphatic malformations, as well as in Phase 2 clinical trial to treat cutaneous venous malformations. It also develops QTORIN rapamycin for the treatment of angiokeratomas and other mTOR-driven skin diseases; and QTORIN pitavastatin for the treatment of disseminated superficial actinic porokeratosis. The company is based in Wayne, Pennsylvania. |
| Long Name | Palvella Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,094,485,504 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_534271315 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -49,297,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,075,552,955 |
| Number Of Analyst Opinions | 15 |
| Open | 142.11 |
| Operating Cashflow | -29,102,000 |
| Operating Margins | 0.0 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Phone | 484 253 1461 |
| Post Market Change | -2.9199982 |
| Post Market Change Percent | -1.9995879 |
| Post Market Price | 143.11 |
| Post Market Time | 1,783,986,953 |
| Previous Close | 144.76 |
| Price Eps Current Year | -26.238998 |
| Price Hint | 2 |
| Price To Book | 8.997536 |
| Profit Margins | 0.0 |
| Quick Ratio | 28.728 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 1.27 |
| Regular Market Change Percent | 0.877317 |
| Regular Market Day High | 146.35 |
| Regular Market Day Low | 137.53 |
| Regular Market Day Range | 137.53 - 146.35 |
| Regular Market Open | 142.11 |
| Regular Market Previous Close | 144.76 |
| Regular Market Price | 146.03 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 208,340 |
| Return On Assets | -0.16603 |
| Return On Equity | -0.34247002 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 14,342,844 |
| Shares Percent Shares Out | 0.165 |
| Shares Short | 2,366,341 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 2,118,329 |
| Short Name | Palvella Therapeutics, Inc. |
| Short Percent Of Float | 0.1867 |
| Short Ratio | 6.81 |
| Source Interval | 15 |
| State | PA |
| Symbol | PVLA |
| Target High Price | 270.0 |
| Target Low Price | 205.0 |
| Target Mean Price | 229.6 |
| Target Median Price | 225.0 |
| Total Cash | 261,852,992 |
| Total Cash Per Share | 18.257 |
| Total Debt | 20,383,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.17 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 103.58872 |
| Two Hundred Day Average Change | 42.441277 |
| Two Hundred Day Average Change Percent | 0.40970942 |
| Type Disp | Equity |
| Volume | 208,340 |
| Website | https://palvellatx.com |
| Zip | 19,087 |